Adjuvant colon chemotherapy guided by tumor DNA results
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether treatment for colon cancer after surgery can be guided by a blood test that looks for leftover cancer signals (ctDNA). It may help some people choose stronger or different chemo based on whether ctDNA is found after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are able to do normal activities at the study level (ECOG 0 or 1).
- Your colon cancer is stage IIB, IIC, or III adenocarcinoma and was fully removed with no visible spread (R0 surgery).
- Your scans from within 45 days before starting shows no metastatic (spread) cancer.
- Your surgery must be within 7 to 60 days before you start the study.
- Your tumor must be microsatellite stable (not MSI-H) or have intact mismatch repair proteins (not dMMR).
- After surgery, you must be able to provide required tumor tissue and blood for the ctDNA blood test (Signatera), with blood ideally at least 14 days after surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a simple blood test to look for tiny bits of tumor DNA after colon cancer surgery. If found, it may help doctors catch any remaining cancer early and guide further treatment.
This Phase 1 study uses a blood test called ctDNA to decide whether and how to adjust treatment in people with colon cancer who still have a small amount of disease left after surgery. If your blood test remains positive, the trial aims to reduce recurrence risk by guiding treatment changes.
This study tests whether giving additional (adjuvant) chemotherapy based on a special blood test—circulating tumor DNA (ctDNA)—can lower the risk of colon cancer coming back. It targets people with stage II–III colon cancer whose blood test is positive for minimal residual disease (MRD) after completing standard chemo.
This trial tests whether a blood test that looks at cancer DNA can help decide whether you need “adjuvant” (extra) chemotherapy after colon cancer surgery. It may help some patients avoid unnecessary chemotherapy while still keeping the cancer from coming back.
This trial uses two blood tests (Signatera and Haystack) to look for tiny bits of cancer DNA after surgery, to find out if the cancer comes back as early as possible. People with stage II, III, or IV colorectal cancer who have had or will have surgery to remove their tumor may join.
This trial tests whether measuring tiny amounts of cancer DNA in the blood before standard treatment can help decide who might safely skip chemotherapy before surgery. It aims to see if a less intensive approach works as well for patients with early rectal cancer.
Hear when a new Stage III Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.